Clinical Trials Logo

Methamphetamine Dependence clinical trials

View clinical trials related to Methamphetamine Dependence.

Filter by:

NCT ID: NCT06288997 Completed - Clinical trials for Methamphetamine-dependence

tACS Intervention for Methamphetamine Addiction

tACS for MUD
Start date: November 21, 2021
Phase: N/A
Study type: Interventional

A growing body of evidence suggests a wide range of brain areas are critical for regulating cognitive control over decisions and involving in drug related cue processing. Previous studies have demonstrated that transcranial alternating current stimulation (tACS) over prefrontal cortex reduces craving for meth dependences. In this study, the investigators investigated whether a current level of 15mA with a patented frequency of 77.5Hz tACS intervention of prefrontal cortex cortices in methamphetamine addiction could reduce the subjective craving and improve the cognitive abilities.

NCT ID: NCT06233799 Not yet recruiting - Clinical trials for Methamphetamine Abuse

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

Start date: May 1, 2024
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) seeking to stop or reduce MA use.

NCT ID: NCT06027814 Recruiting - Clinical trials for Medication Adherence

MHealth Incentivized Adherence Plus Patient Navigation

MIAPP
Start date: January 3, 2024
Phase: N/A
Study type: Interventional

Polysubstance use involving opioids and methamphetamine is emerging as a new public health crisis. Patients with opioids and methamphetamine use often experience serious medical complications requiring hospitalization, which provides an opportunity to offer addiction treatment. Yet linkage to outpatient treatment post-discharge is suboptimal and methamphetamine exacerbates outcomes. The investigators propose to pilot test "MHealth Incentivized Adherence Plus Patient Navigation" (MIAPP) to promote treatment linkage and retention for patients with opioid use disorder (OUD) and methamphetamine use who initiate buprenorphine in the hospital. The investigators Aim is to perform a two-arm, pilot randomized clinical trial (n=40) comparing MIAPP + treatment-as-usual (TAU) versus TAU alone on outpatient medication for opioid use disorder (MOUD) linkage within 30 days (primary) and 90-day retention on medications (secondary) among hospitalized patients with OUD and methamphetamine use.

NCT ID: NCT05916989 Completed - HIV Infections Clinical Trials

Stimulant Use and Methylation in HIV

Start date: September 30, 2018
Phase:
Study type: Observational

This study will leverage extracted leukocyte DNA specimens from a completed NIH-funded project to examine the efficacy of a behavioral intervention model that reduced stimulant use on DNA methylation over 6 months.

NCT ID: NCT05854667 Recruiting - Addiction Clinical Trials

Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users

Start date: December 5, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn if administering a high dose stimulant with Contingency Management reduces days of use in adults who use methamphetamine better than the usual treatment provided by the clinic. The main questions the trial aims to answer are: Is a high dose stimulant better than a placebo and usual treatment at helping reduce the number of days they use methamphetamine? Is a high dose stimulant with contingency management better than placebo and usual treatment at helping people reduce the number of days they use methamphetamine? Participants will be placed randomly into one of four groups: 1. Usual treatment and placebo 2. Usual treatment, placebo and contingency management 3. Usual treatment and high dose stimulant 4. Usual treatment, high dose stimulant and contingency management Participation includes the following: 1. Participants will receive medication or placebo weekly for 15 weeks. 2. Participants will attend the clinic for weekly treatment 3. Participants will attend the clinic once every 2 weeks for study visits. Each visit will take about an hour to complete. At these visits, participants will be asked to provide a urine sample and complete questionnaires.

NCT ID: NCT05334914 Not yet recruiting - Clinical trials for Methamphetamine Abuse

ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

This study aims to assess the feasibility, acceptability and preliminary effectiveness of Acceptance Commitment Therapy, in conjunction with motivation enhancement, and the use of the ChillTime App, in reducing methamphetamine use in women with MUD with or without co-occurring psychiatric disorders. This intervention is designed to be delivered remotely (e.g., participants can complete the entire study from home), with the option for in person attendance if it is not feasible or safe for participants to attend from home.

NCT ID: NCT05283304 Terminated - Clinical trials for Methamphetamine-dependence

Monthly Injectable BUP for MA Use Disorder (MURB) Trial

CTN-0110
Start date: March 24, 2023
Phase: Phase 2
Study type: Interventional

This study is a 12-week randomized, double-blind, placebo-controlled trial that will investigate the use of injectable buprenorphine (BUP-Inj) compared to injectable placebo (PBO-Inj) for the treatment of methamphetamine use disorder (MUD) among individuals with mild co-use of opioids.

NCT ID: NCT05162391 Recruiting - Clinical trials for Methamphetamine-dependence

Inflammation in Methamphetamine and STIs (IMSTI)

IMSTI
Start date: May 31, 2022
Phase: N/A
Study type: Interventional

This clinical trial aims to investigate the effects of a decline in methamphetamine use on rectal inflammatory cytokine levels, substance use contexts, and HIV/STI risk behavior. This clinical trial also seeks to evaluate joint effects of methamphetamine use and rectal gonorrhea/chlamydia infection on rectal inflammatory cytokine levels. The proposed trial will consist of 40 MSM, half with rectal gonorrhea/chlamydia infection at enrollment (n=20), with methamphetamine use disorder that will receive contingency management for methamphetamine reduction. Following baseline measurement, participants will be observed over the course of 8 weeks, where participants will complete behavioral surveys, provide urine for drug testing, and rectal samples for measurement of rectal inflammatory cytokine levels.

NCT ID: NCT05128071 Recruiting - Clinical trials for Methamphetamine-dependence

PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)

Start date: February 4, 2022
Phase: Early Phase 1
Study type: Interventional

The PRevention Of Methamphetamine Use among Postpartum Women Trial (PROMPT) is randomized controlled trial of postpartum individuals with methamphetamine use disorder to 12 weeks of 200 mg oral micronized progesterone twice daily or placebo. The aims of this study are to assess the feasibility, safety and preliminary efficacy of micronized progesterone for the prevention of return to methamphetamine use. A secondary aim is to assess participant's salivary levels of allopregnanolone with methamphetamine cravings. This study has the potential to provide effective interventions to prevent methamphetamine use among postpartum women.

NCT ID: NCT05034874 Active, not recruiting - Clinical trials for Methamphetamine Abuse

Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200

OUTLAST
Start date: June 9, 2022
Phase: Phase 2
Study type: Interventional

This Phase 2 study will evaluate the safety and efficacy of monthly intravenous doses of IXT-m200 in treatment-seeking individuals with methamphetamine (METH) use disorder. The hypothesis are that following an initial relapse, IXT-m200 will reduce the occurrence of stimulant-positive saliva samples compared to placebo and improve the signs and symptoms of METH Use Disorder (MUD).